Plasma D-dimer and severity in adult community-acquired pneumonia
Association Between Elevated Plasma D-dimer in Adult Community-acquired Pneumonia Patients and Severity of Inflammatory Response and Survival
This project will see if higher blood D-dimer levels are linked to stronger inflammation and worse survival in adults with community-acquired pneumonia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07199530 on ClinicalTrials.gov |
What this trial studies
This observational study will enroll at least 50 adults with community-acquired pneumonia seen or admitted to Ain Shams University Hospitals in Cairo. Investigators will collect blood for plasma D-dimer and routine labs (white blood cell count, CRP), obtain chest x-rays, and calculate CURB-65 severity scores. The analysis will examine relationships between D-dimer levels, markers of inflammatory response, clinical severity scores, and survival. Patients with coagulation disorders, active cancer, other chronic diseases, or signs of COVID-19 will be excluded and no experimental treatments are administered.
Who should consider this trial
Good fit: Adults aged 18 or older with clinically and radiologically confirmed community-acquired pneumonia seen or admitted to Ain Shams University Hospitals who do not have signs of COVID-19 and consent to blood sampling are ideal candidates.
Not a fit: Patients with known coagulation disorders, active cancer, other chronic diseases, or clinical or radiologic signs of COVID-19 are excluded and thus unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, measuring D-dimer could help clinicians estimate illness severity and survival risk in CAP and inform treatment decisions.
How similar studies have performed: Previous studies have often reported that higher D-dimer levels correlate with worse outcomes in pneumonia, so this approach has supporting evidence though findings are not entirely consistent.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who will be admitted to the Chest department, or coming to the outpatient clinic at Ain-Shams University Hospitals with CAP, and have the following inclusions: 1. age ≥18 years 2. diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence. Exclusion Criteria: * Patients with a history of coagulation disorders, cancer, or other chronic diseases, or refusal to participate. * patients who have any clinical or radiological signs suggesting COVID-19 pneumonia.
Where this trial is running
Cairo
- Ain Shams University hospitals — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Hieba Gamal Ezzelregal
- Email: hiebagamal24@med.asu.edu.eg
- Phone: +201002041611
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.